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We are incorporating these criteria into the management procedures of
government agencies sponsoring primate research.
The committee has also been concerned with the allocation of primate supplies. In view of the uncertainties of current and future primate species, the time
may soon be here when there will be insufficient numbers of one or more species
to meet minimum health needs of the U.S. The plan provides an outline to be
followed in such a situation. When such difficult choices have to be made, the
priorities of distribution will be: 1) to fulfill legal requirements; 2) for use in
breeding colonies; and 3) for other research and development purposes.
Since the legal requirements are developed by government agencies as a
result of their regulatory authority, the National Primate Plan recommends that
any proposed federal guideline, standard, or regulation which either requires
primate usage or restricts their availability be submitted to the committee to
assess the potential impact on the overall national supply. We are also encouraging users to reexamine their needs for acceptable alternatives as well as encouraging the development of new techniques and procedures that will further
reduce their primate requirements. In addition, we are encouraging researchers
to make the specifications for animals as rational and precise as possible. Finally,
we must consider the ethical responsibilities shared by all of us who provide and
use primates as research animals. Humane care issues, while not new, have
become amplified in recent years. We must be prepared to deal with these issues
which are surrounded by so much emotion.
The biomedical community is searching for. alternatives to animal experimentation not only for humane, but also for economic reasons. Unfortunately, alternatives to testing the combined complex physiological systems found in
the intact animal are currently quite limited, and to meet present needs can only
be considered complementary or supplementary. However, such procedures may
help to screen agents requiring testing and thus help to slow down the increasing
requirements for animals.
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Scientific Issues and Regulation
of Primate Use
Andrew N. Rowan*
Abstract
Some of the patterns of use of nonhuman primates in the USA and Europe are
outlined and a few specific examples of inappropriate and/or unnecessary use are
described. The primate research resources program in the USA is examined and
some suggestions as to how the program could be made more responsive to
humane and conservation concerns are presented.

Conclusion
In summary, a number of important steps have been taken to assure adequate primate supplies. The research done with these animals is essential to provide knowledge of benefit to all people in all nations. A balanced program is
needed worldwide that includes conservation of wild populations; improvement
of wildlife management programs; better means of capture, conditioning, and
shipping; increased domestic breeding of animals; and judicious use of these
precious resources.
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The National Primate Plan (U.S. Dept. of Health, Education and Welfare,
1980) opens with these words: "A severe and long-term shortage of nonhuman
primates threatens the continuation of many essential health activities." It is certainly true that the supply of nonhuman primates has been disrupted over the
past few years in India, Bangladesh and Malaysia. However, it is by no means
clear that the continuation of essential health activities is threatened.
The National Primate Plan specifically notes that the use of nonhuman
primates in lifetime testing of steroid contraceptives is so critical that it is required with a force equivalent to that of law (Food and Drug Administration,
1969). However, the steroid metabolic patterns of the primates used in this
testing are sufficiently different (Shackleton and Mitchell, 1975) to prevent meaningful extrapolation of results to human beings. Data gleaned from studies on
*Dr. Rowan is the Associate Director of the Institute for the Study of Animal Problems, 2100 L St.
N.W., Washington, DC 20037. This paper is an edited version of a text prepared for and presented at
the Institute for the Study of Animal Problems symposium on Nonhuman Primates in Biomedical Programs, 15 October 1980, San Francisco, California.
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animals involving chronic administration of a new steroid contraceptive for
several years are virtually useless for regulatory purposes. Therefore, in terms of
health hazard evaluation for humans, these chronic tests are a waste of time,
money and animals.
Similarly, the National Primate Plan notes that between 5,000 and 6,000
macaques are required annually for vaccine production and testing, mostly for
poliomyelitis vaccine. This represents a considerable reduction over the late
1950's when hundreds of thousands of rhesus macaques were used every year in
the development and production of polio vaccines (LeCornu and Rowan, 1979).
This reduction has occurred, in part, through the development of better methods
of harvesting monkey kidney cells. In Denmark, for example, these methods have
resulted in a reduction in the number of monkeys required from 400 to 40 (Fennestad and Petersen, 1979). However, it is now technically possible to eliminate
the present demand for macaques without jeopardizing human safety.
Currently, two types of polio vaccine are produced: the live, attenuated
(Sabin) vaccine and the inactivated (Salk) vaccine. The virus for both types can be
grown in human cell culture although the yield from a given quantity of diploid
human cells is lower than in early generation monkey cell cultures (Beale, 1979).
Only small amounts of virus are needed for immunization with the Sabin vaccine
(the virus grows in the vaccinee), but larger quantities of the Salk vaccine are required, thus making it more expensive than the Sabin. The price of the Salk vaccine could, however, be reduced by using cell-suspension cultures or microcarrier techniques to produce a larger virus yield from a given volume of culture
fluid (Petricciani eta/, 1979). The technology is being developed and thus the
economic need for monkey kidney cell cultures could possibly be eliminated.
This would have health advantages since monkey kidney cell cultures are
notorious for their contamination by extraneous agents, and up to 50% of
monkey kidney ceil cultures may have to be discarded because of viral contam in ants (Beale, 1979).
Both vaccines are tested in several animal species, including monkeys. It is
difficult to envisage a total replacement for monkeys in Sabin vaccine neurotoxicity testing, but one could certainly eliminate the monkey test for the Salk vaccine. The cell culture test for live virus particles is more sensitive (safer?) than the
monkey test (Beale, 1978) and the World Health Organi~ation (WHO) is considering a recommendation for a suitable cell culture test as a replacement method (F.
Perkins, personal communication). Therefore, with a few technical modifications,
and a change of attitude among regulators one could eliminate the need for
monkeys to test the inactivated vaccine. However, memories of the Cutter
disaster, when over 200 children contracted paralytic poliomyelitis after receiving an inadequately inactivated batch of Salk vaccine, still loom large in many
minds despite our much greater understanding of the manufacturing process and
our ability to guard against a repetition of such a disaster.
Almost twenty percent of the projected U.S. demand for primates is accounted for by the polio vaccine program. A switch from the Sabin to the Salk
vaccine, the use of cell lines (human?) and microcarrier culture techniques, and
dropping the requirement for the monkey test in Salk vaccine production could
virtually eliminate this need. There are a few minor technical problems to be
solved and much economic, political and bureaucratic inertia and resistance to
overcome. Finally, it should be noted that there may still be some need for the
38
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Sabin vaccine to deal with polio outbreaks since even Salk acknowledges that
the Sabin vaccine is more effective under these circumstances (Boffey, 1977). The
respective proponents of the Salk and Sabin vaccines are involved in a bitter
argument over which is better in terms of effectiveness and safety (Editorial,
1977; Salk and Salk, 1978). Where one has a well-disciplined community (as in
Sweden), there is no doubt that the inactivated Salk vaccine is effective, but
there are questions as to whether it can provide the same level of protection in
Third World countries. The testing issue has also not yet been decided by the
World Health Organization and even if the WHO does produce a new recommendation, inertia will militate against authorities replacing the old monkey test.
Nonetheless, it is clear that the use of nonhuman primates is not an essential requirement for the production and testing of polio vaccine.
While the use of monkeys in polio vaccine and oral contraceptive testing is a
story of conflicting scientific data, conservative attitudes and inertia, the
laboratory chimpanzee situation is a catalogue of mismanagement in which the
chimpanzees come out a very distant last. In 1977, the National Institutes of
Health (NIH) circulated a draft primate plan in which an annual need for 180
chimpanzees was estimated (Interagency Primate Steering Committee, 1977).
However, in 1978, the Interagency Primate Steering Committee (IPSC) published
a report of a task force on chimpanzees which estimated a total annual demand
of about 700 chimpanzees (Table 1).
TABLE 1-IPSC Task Force Estimate of the Number of Chimpanzees Being
Used in or Required for Biomedical Programs.

Current Use

Projected
Future Annual Demand

Behavioral Sciences

(not given)

50

Infectious Diseases
Hepatitis
Other

156
46

314
46

(not given)

45

Hematology, immunology
& immunogenetics

150

50

Toxicology& pharmacology

200

100

Reproductive biology

85

50

Other (aging, aerospace, etc.)

25

80

662+

735

Field of Research

Neurological Diseases

TOTALS

Not only was this projection vastly inflated, but the reasons given for why
the chimpanzees were so necessary were gross overstatements (Rowan, 1979). It
is now commonly (if privately) accepted among laboratory primatologists that
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this report exaggerated the demand, presumably to make a case for additional
importation from the wild as well as for more support for domestic breeding programs. There are currently 1100+ chimpanzees in laboratory and/or breeding
facilities in the United States. These animals produce between fifty and seventy
offspring annually, but a number of the infants die before reaching maturity. Little concerted action is being taken to improve this state of affairs and, in fact,
one of the most successful breeding colonies has been broken up (and may well
be destroyed) as the result of inadequate coordination and bad planning by funding agencies.
Several years ago, the Laboratory for Experimental Medicine and Surgery in
Primates (LEMSIP) was awarded a contract for chimpanzee breeding for a
hepatitis study program by the National Heart, Lung and Blood Institute (NHLBI).
When the contract came up for renewal, it was put out for competitive bids and
another three year contract awarded to the Southwest Foundation for Research
and Education (SFRE). The stated reason for moving the contract was that SFRE
had quoted a price that was half LEMSIP's projection of $1.1 million. This judgment has been challenged, and New York University has sued NIH on the grounds
that the issuing of the RFP (Request for Proposal) and review of the submissions
had been mismanaged. Meanwhile, the chimpanzees still had to be moved. Over
a period of two months, 73 animals were trucked from New York to Texas under
conditions which, at best, could only be described as highly stressful. It is not particularly surprising that nine animals have subsequently died and that the
breeding program has been totally disrupted. It is pertinent to note that LEMSIP's
1978 breeding success rate of 35% (J. Moor-J ankowski, personal communication)
was among the best (if not the best) in the country.
This particular saga has been related in order to illustrate how the animals
come off second best, especially when the situation is highly politicized, as in the
LEMSIP-SFRE-NHLBI dispute. The chimpanzees were treated as chattel, to be
picked up at a moment's notice and hauled thousands of miles across the United
States without regard to anything more than mere survival. It was predicted that
the move would disrupt the colony and that it would never achieve the stated
goals of the contract, namely, ten offspring per annum. This prediction has, unfortunately, been borne out by subsequent events, and SFRE looks as if it will be
hard-pressed to maintain the colony numbers, let alone increase the colony by
thirty healthy offspring by june, 1982. However, NHLBI staff responsible for
managing this contract have indicated that this does not concern them since they
anticipate that they will no longer need a special chimpanzee colony after
another year or two. It is not clear what will happen to the remaining animals
when the contract expires.
Apart from the problems surrounding the long-term maintenance of the colonies of great apes (and most are kept in facilities which are grossly inadequate
considering the animals' social and psychological needs [d. McGrew, 1981])
there are other aspects of primate research in the United States which give cause
for concern. It has been stated that the seven primate research centers around
the country fail, with one or two exceptions, to provide adequate value for the
money and top class research (NIH, 1976; Hobbs and Bleby, 1976). By contrast,
LEMSIP, which, ironically, is on the verge of closing down, has been acknowl-
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edged to provide excellent value for the money (Hobbs and Bleby, 1976). One of
the main problems is that the Primate Research Center (PRC) program has
become a self-perpetuating oligarchy within the Animal Resources branch of
NIH's Division of Research Resources. In 1975, the PRCs received $12.5 million
for core support out of a total of $17.1 million allocated to laboratory animal
resources. They have since maintained this dominant role within the funding program. Because of the financial muscle behind the PRC program any efforts to
reform the program have resulted in cosmetic changes rather than the necessary
major overhaul. The Bolt, Beranek and Newman (BBN) consultant panel (NIH,
1976) came out with some relatively hard-hitting proposals for reform, but a
subsequent review of the PRC program (NIH, 1979), stimulated by the BBN
report, either undercut many of the BBN proposals or was so general and vague
as to be virtually useless. According to a member of the second review, the panel
did not feel free to entertain any proposals which would have resulted in radical
changes in the extent or scope of the primate center program (L. Rosenblum, personal communication). However, the panel did note that the quality of the scientists in the PRCs was below par and that the centers do not have the reputation of
being "the place to be."
The undermining effect of the second review was most unfortunate since
one of the BBN proposals could be developed to provide answers to many of the
problems which currently plague the primate research effort. The BBN panel suggested that a Primate Utilization Authority be established to oversee all primate
breeding and use in the United States. This concept is, however, somewhat
limited. It needs to be expanded to incorporate conservation questions and to include representation from humane and conservation groups. After all, the Endangered Species Scientific Authority has research community representation.
Also, the name should be changed to the National Primate Study Authority
(NPSA). There are other precedents for such an organization; for example, the National Toxicology Program is essentially a consortium of federal agencies involved in bioassays and the development of new methods.
The NPSA should include adequate representation from user groups such as
NIH and the Department of Defense, as well as from conservation and humane
organizations. The NPSA should have oversight for the immediate primate
breeding and research programs as well as for the long-term fate of the animals.
It should look carefully at the proposed needs for primates and determine just
how essential some of the research really is. For example, a European Economic
Community task force (Committee on Medical and Public Health Research, 1979)
identifies the essential primate research needs (Table 2) in a more limited manner
than the National Primate Plan (Dept. of Health, Education and Welfare, 1980). In
addition, greater attention needs to be focused on primate housing and on some
of the research techniques, especially in behavioral studies. If a primate really is
a good model of human behavior patterns (such as addiction, depression, antisocial activity), then it presumably has very similar needs to humari beings which
should be acknowledged and met. If it is not a good model of the human psyche
then we should question whether such research should be done at all.
For the great apes, we need to reassess our priorities completely. If the use
of these animals is to be justified, then we consider that the following minimum
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conditions should be met: First, the animals should be kept under conditions
which, as far as possible, meet their physical and social requirements. Second,
breeding programs should be established to obviate any current or future importation from the wild. Third, the research project must not be terminal. Fourth,
adequate provisions should be made for the lifetime of the animals being used,
and it must be recognized that great apes cannot be moved around as though
they were pieces of machinery. It must be stressed that these are mi~imal conditions; ideally, we should accord the great apes the same quality of facilities and
respect that we accord human subjects.
In conclusion, we accept that there are some legitimate and essential uses of
primates in biomedical programs, but we do not consider the present level
necessary or the current controls adequate. The conservation and humane concerns must be given adequate consideration and the primate program totally reevaluated. The Primate Research Centers currently receive over $16 million in
core support. It is arguable that far better use could be made of all or a portion of
this money if it were allocated to the development of other types of biomedical
technology. The development of primate research models appears to have high
prestige and yet there is no clear reason why it should. One can only speculate
that such prestige stems from an anthropomorphic bias derived from the fact
that primates are our close evolutionary relatives. If this is indeed the case, then
we need to consider their interests much more closely.

TABLE 2- Primate Use for Biomedical Research and Health Care(EEC, 1979)*
Species

Research or Other Activity for which
Availability of Primate Species is:
Essential

Highly Desirable

Chimpanzee

Hepatitis B (vaccine testing);
Hepatitis "non-A-non-B."

Hepatitis A; Certain cardiovascular diseases; Antifertility;
Production of antisera.

Macaque (Rhesus and
Cynomolgus)

Production and testing of
vaccines (mainly polio); Toxicology and teratology.

Reproductive physiology and antifertility; Endocrinology; Diagnostic virology; Immunology and
transplantation.

New World Monkeys

Hepatitis A (marmosets);
Hepatitis "non-A-non-B"
(marmosets); DNA and RNA
tumor viruses; Hematopoietic
chimaerism (marmosets);
Malaria (owl monkeys).

Teratology, reproductive
physiology and antifertility;
Cardiovascular diseases
(mainly squirrel monkeys);
Pharmacology and toxicology
(mainly squirrel monkeys);
Immunology and transplantation;
Slow virus diseases.

Baboon

Cancer virology; Reproductive
physiology.

*From Reports and Memoranda of the Working Group on the Use and Supply of Non-human Primates
for Biomedical Purposes. Committee on Medical Research Commission of the European Communities,
Brussels, 1978.
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conditions should be met: First, the animals should be kept under conditions
which, as far as possible, meet their physical and social requirements. Second,
breeding programs should be established to obviate any current or future importation from the wild. Third, the research project must not be terminal. Fourth,
adequate provisions should be made for the lifetime of the animals being used,
and it must be recognized that great apes cannot be moved around as though
they were pieces of machinery. It must be stressed that these are mi~imal conditions; ideally, we should accord the great apes the same quality of facilities and
respect that we accord human subjects.
In conclusion, we accept that there are some legitimate and essential uses of
primates in biomedical programs, but we do not consider the present level
necessary or the current controls adequate. The conservation and humane concerns must be given adequate consideration and the primate program totally reevaluated. The Primate Research Centers currently receive over $16 million in
core support. It is arguable that far better use could be made of all or a portion of
this money if it were allocated to the development of other types of biomedical
technology. The development of primate research models appears to have high
prestige and yet there is no clear reason why it should. One can only speculate
that such prestige stems from an anthropomorphic bias derived from the fact
that primates are our close evolutionary relatives. If this is indeed the case, then
we need to consider their interests much more closely.

TABLE 2- Primate Use for Biomedical Research and Health Care(EEC, 1979)*
Species

Research or Other Activity for which
Availability of Primate Species is:
Essential

Highly Desirable

Chimpanzee

Hepatitis B (vaccine testing);
Hepatitis "non-A-non-B."

Hepatitis A; Certain cardiovascular diseases; Antifertility;
Production of antisera.

Macaque (Rhesus and
Cynomolgus)

Production and testing of
vaccines (mainly polio); Toxicology and teratology.

Reproductive physiology and antifertility; Endocrinology; Diagnostic virology; Immunology and
transplantation.

New World Monkeys

Hepatitis A (marmosets);
Hepatitis "non-A-non-B"
(marmosets); DNA and RNA
tumor viruses; Hematopoietic
chimaerism (marmosets);
Malaria (owl monkeys).

Teratology, reproductive
physiology and antifertility;
Cardiovascular diseases
(mainly squirrel monkeys);
Pharmacology and toxicology
(mainly squirrel monkeys);
Immunology and transplantation;
Slow virus diseases.

Baboon

Cancer virology; Reproductive
physiology.

*From Reports and Memoranda of the Working Group on the Use and Supply of Non-human Primates
for Biomedical Purposes. Committee on Medical Research Commission of the European Communities,
Brussels, 1978.
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